awmsg logo



raltegravir (Isentress®)


Reference No. 2366

Publication date:
10/12/2015


Appraisal information

raltegravir (Isentress®) 100 mg granules for oral suspension


Company: Merck Sharp & Dohme Ltd
BNF category: Infections
NMG meeting date: 07/10/2015
AWMSG meeting date: 11/11/2015
   
   
Submission Type: Limited Submission
Status: Recommended with restrictions
Advice No: 3515
Ministerial ratification: 09/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Raltegravir (Isentress®) 100 mg granules for oral suspension, in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, children, toddlers and infants from the age of four weeks are recommended as an option for restricted use within NHS Wales. Raltegravir (Isentress®) 100 mg granules for oral suspension should be restricted for use in patients who are resistant or intolerant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs), or for whom these options are compromised due to drug–drug interactions.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download